Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
about
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentPhase I trials of antitumour agents: fundamental conceptsA Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical TrialsClinical Translation of Nanomedicine.ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasiaPenile cancer: current therapy and future directions.The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Strengthening Interactions between Statisticians and Collaborators: Objectives and Sample SizesNovel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements.Insight into early-phase trials for lung cancer in the United StatesPredictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumorsRadiation quality, like art, consists in drawing the line somewhere.Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaEarly phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.Systems pharmacology, pharmacogenetics, and clinical trial design in network medicineDose-finding designs using a novel quasi-continuous endpoint for multiple toxicitiesDetermination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013Commentary: Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer.Patient knowledge on reporting adverse drug reactions in Poland.The role of age on dose-limiting toxicities in phase I dose-escalation trials.Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.Dose-toxicity models in oncology.Adaptive designs for dual-agent phase I dose-escalation studies.Risks and benefits of phase 1 clinical trial participation.Reading between the lines; understanding drug response in the post genomic era.Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)Early phase cancer clinical trials: design, ethics and future directions.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.The changing landscape of phase I trials in oncology.Evaluating the role of phase I expansion cohorts in oncologic drug development.Small-sample behavior of novel phase I cancer trial designs.A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.Selection of the initial design for the two-stage continual reassessment method.
P2860
Q26823418-29B8D024-D4C5-4A61-89D5-21E19F0A33D1Q26862558-DB2A3E1E-2B24-45C9-8F53-EA347AA1CA95Q26865346-E64556A9-53BF-4F95-8AA5-0A2377F6B55AQ28551817-09C9CA85-C242-4DB5-971F-4E13DBC59FB5Q30355939-AF3433C2-D823-4C87-8279-442A01C0B924Q33573626-999850F7-407D-4295-A156-7DE4783D8204Q33718095-16AE9908-C684-47B6-97E1-6DF8E178871BQ33732581-C636DFEA-018C-407F-BDE6-595F1C8B8552Q35136424-F6F75E66-D9BB-428A-B7E5-9122A1D2685DQ35545901-31869910-D32B-4410-80BC-AA767781AE4BQ36014074-B6240BC6-9E59-497D-A60F-B1658D727877Q36121135-C7E91CF5-D563-45E1-B44A-BD456EBCFBB2Q36326389-A75DAA70-C772-4822-8241-CB1BA94D5513Q36507559-23A4FD0C-15C4-459F-9102-D9F82D937508Q36959835-2DFB2BBB-9EB8-4180-9832-0B20CE3B7BDDQ37019668-F347EF0D-50F1-4340-971C-3F26313579CBQ37053833-4D9E6611-1DD0-47BF-BD47-0101EED57FDDQ37096644-0A99D61A-4111-4C30-903F-28307EF50D30Q37128756-C1C74A12-A762-4878-9F90-402ADAD3E900Q37199477-A397DAE5-E3BC-4F6A-AF1F-80C6FE6AF964Q37270128-C1497517-C45C-4C91-BA1E-57E8D19D0FF3Q37496388-B7553D85-D7B3-41AA-9092-472005B76FE1Q37525416-20AED7E5-22AC-404D-A144-3AEF6D6054F4Q37551882-93AB60F4-4203-4006-91AC-4823B1956649Q37552648-998CDA9C-19A1-40FE-AAAB-FF1A480419EEQ37570408-E7487B2B-97DC-47EF-8C11-FD4325B36355Q37829437-9CFAD00F-D8F2-4F88-A97E-FC58113F25F7Q38090897-0AFFA8D0-29F2-49FB-B159-6CDB02AB9897Q38222465-02A91A0A-F8D9-41A0-B5B1-127140BE305DQ38222600-CD72E795-9F2C-4EA9-BFF6-877C0BB1949DQ38242725-2CD214C4-82BF-40AC-B7D0-A9486913C1F2Q38542427-4125B4F5-5410-4646-B645-EA24C680EF9AQ38583655-2A71FEB2-8212-4746-9E83-E7F60A569FD2Q38629203-DBE620DC-7706-4F05-B75F-3BB430A7BEC2Q38975518-57446DEF-4AFB-4FA7-A5A6-00FE21AAE65AQ39479987-8F35D6BC-9831-49B4-A884-41C834A77733Q40298545-3D1251F1-23F0-44A3-8373-D370DD4B0ACBQ43846394-C3AEEBB3-D562-4DF5-98DC-7545898D137DQ44482782-25A76DFB-FCCC-4CAA-BF00-FA41563E3A09Q47356919-9FA7E2DF-95DF-4D37-9995-E47C846FE364
P2860
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Approaches to phase 1 clinical ...... ional drug steering committee.
@en
Approaches to phase 1 clinical ...... ional drug steering committee.
@nl
type
label
Approaches to phase 1 clinical ...... ional drug steering committee.
@en
Approaches to phase 1 clinical ...... ional drug steering committee.
@nl
prefLabel
Approaches to phase 1 clinical ...... ional drug steering committee.
@en
Approaches to phase 1 clinical ...... ional drug steering committee.
@nl
P2093
P2860
P1476
Approaches to phase 1 clinical ...... ional drug steering committee.
@en
P2093
Elizabeth Garrett-Mayer
Larry Rubinstein
Lillian L Siu
S Percy Ivy
P2860
P304
P356
10.1158/1078-0432.CCR-09-1961
P407
P577
2010-03-09T00:00:00Z